

# Yiying Cai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2635243/publications.pdf>

Version: 2024-02-01

29  
papers

548  
citations

687363

13  
h-index

677142

22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

937  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 719421.	3.9	3
2	Whole genome sequencing reveals hidden transmission of carbapenemase-producing Enterobacterales. <i>Nature Communications</i> , 2022, 13, .	12.8	16
3	Estimating the excess bed days and economic burden of healthcare-associated infections in Singapore public acute-care hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-4.	1.8	4
4	In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> With Different Carbapenemases and Sequence Types. <i>Frontiers in Microbiology</i> , 2021, 12, 779988.	3.5	5
5	Determining the Development of Persisters in Extensively Drug-Resistant <i>Acinetobacter baumannii</i> upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
6	Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study. <i>Antibiotics</i> , 2020, 9, 451.	3.7	14
7	The impact of healthcare associated infections on mortality and length of stay in Singapore—A time-varying analysis. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1315-1320.	1.8	6
8	Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant Enterobacterales. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 579462.	3.9	10
9	Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria. <i>Microorganisms</i> , 2020, 8, 1489.	3.6	1
10	In vitro Pharmacodynamics and PK/PD in Animals. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 105-116.	1.6	7
11	Molecular mechanisms of azole resistance in <i>Candida</i> bloodstream isolates. <i>BMC Infectious Diseases</i> , 2019, 19, 63.	2.9	34
12	Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case—control study. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 657-662.	2.5	13
13	Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> : A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2018, 76, 48-57.	3.3	16
14	Integrated pharmacokinetic&ndash;pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1591-1596.	2.7	6
15	Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	10
16	Prevalence of Healthcare-Associated Infections and Antimicrobial Use Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National Point Prevalence Survey. <i>Clinical Infectious Diseases</i> , 2017, 64, S61-S67.	5.8	97
17	Candidemia in a major regional tertiary referral hospital — epidemiology, practice patterns and outcomes. <i>Antimicrobial Resistance and Infection Control</i> , 2017, 6, 27.	4.1	24
18	Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant <i>Escherichia coli</i> in Time-Kill Studies and in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14

#	ARTICLE	IF	CITATIONS
19	Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. <i>Microorganisms</i> , 2016, 4, 13.	3.6	26
20	From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB). <i>PLoS ONE</i> , 2016, 11, e0158740.	2.5	13
21	Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4013-4022.	3.2	24
22	<i>In Vitro</i> Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant <i>Enterobacter cloacae</i> with Decreased Susceptibility to Polymyxin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5238-5246.	3.2	14
23	A multidisciplinary antimicrobial stewardship programme safely decreases the duration of broad-spectrum antibiotic prescription in Singaporean adult renal patients. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 91-96.	2.5	15
24	Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours. <i>PLoS ONE</i> , 2015, 10, e0140446.	2.5	10
25	Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Infection</i> , 2015, 70, 309-311.	3.3	20
26	<i>In Vitro</i> Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2515-2524.	3.2	39
27	Polymyxin B versus colistin: an update. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1481-1497.	4.4	80
28	A procalcitonin-based guideline promotes shorter duration of antibiotic use safely in acute pancreatitis. <i>Journal of Infection</i> , 2014, 69, 412-415.	3.3	8
29	Vancomycin-resistant Enterococci in Singaporean hospitals: 5-year results of a multi-centre surveillance programme. <i>Annals of the Academy of Medicine, Singapore</i> , 2012, 41, 77-81.	0.4	6